News

Saint Luke’s Mid America Heart Institute was the first in Kansas and Missouri, and one of only 27 US institutions, to participate in PULSED AF clinical trial.

The groundbreaking STEP-HFpEF study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named one of the top advances by the American Heart Association.

TAVR in asymptomatic and minimally symptomatic patients is associated with a high survival rate, but relatively minor improvements, according to new research.

The heart transplant team at Saint Luke’s Mid America Heart Institute recently performed its 1,000th transplant, reaching a prestigious milestone less than 25 hospitals in the nation have managed to accomplish.

AARP talked to Dr. James O'Keefe about the benefits of omega fatty acids and how much you should be consuming.

A growing body of evidence correlates shorter running sessions to significant health benefits, especially those regarding longevity and mental health.

A man from Columbia, Missouri, got a new heart and a second chance at life, marking the 1,000th heart transplant at Saint Luke's Mid America Heart Institute.

Semaglutide improved symptoms, physical limitations, and exercise capacity in patients with obesity and heart failure across the spectrum of left ventricular ejection fraction.

Dr. Timothy Bateman spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.

Saint Luke’s program becomes the 23rd institution in the U.S. to perform 1,000 heart transplants.